Tenderwize
Retour à la recherche

Open house discount agreements for Botulinumtoxin Typ A Xeomin

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jan 05, 2027 · 129 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Botulinumtoxin Typ A, Fertigarzneimittelbezeichnung Xeomin(R), ATC M03AX21

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No information on volumes or expected discounts; revenue potential is unknown.

Manual paper submission requires two original copies; electronic submission requires qualified electronic signature.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Non-exclusive discount agreements for Botulinumtoxin Typ A (Xeomin) under §130a Abs. 8 SGB V.
  • Contractors are pharmaceutical companies that meet eligibility criteria.
Afficher le résumé complet

This is an open-house model for non-exclusive discount agreements on Botulinumtoxin Typ A (Xeomin) with AOK Bayern in Germany. It is not a traditional procurement; any eligible pharmaceutical company can join. The contract runs from March 1, 2025 to February 28, 2027, with possible termination. No estimated value is provided. Only one lot exists. Eligibility is proven via a signed self-declaration of reliability. Submission can be in paper or electronic form with qualified signature. Documents are available on dtvp.de.

Risques

No information on volumes or expected discounts; revenue potential is unknown.

Manual paper submission requires two original copies; electronic submission requires qualified electronic signature.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Only pharmaceutical companies can participate.

Certifications

  • Documents must be in German or accompanied by a certified German translation.

Administrative

  • Must submit a signed self-declaration of reliability.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house discount agreements for Botulinumtoxin Typ A Xeomin

Non-exclusive discount agreements for the active ingredient Botulinumtoxin Typ A, finished medicinal product Xeomin (R), ATC M03AX21. Contractors can join anytime until January 5, 2027. The agreement ends February 28, 2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Feb 2025 - Feb 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jan 05, 2027

Détails de la procédure

Date de publication
16 Jan 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
34179-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30